



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 30, 2022

David Kirn, M.D.  
Chief Executive Officer  
4D Molecular Therapeutics, Inc.  
5858 Horton Street #455  
Emeryville, California 94608

**Re: 4D Molecular Therapeutics, Inc.  
Registration Statement on Form S-3  
Filed August 23, 2022  
File No. 333-267013**

Dear Dr. Kirn:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7967 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Mark V. Roeder